Antiretroviral Therapy – Changes of Basic Laboratory Parameters in Hiv-Infected Bulgarian Patients

1. Еленков, И., Н. Янчева, Т. Червенякова и сътр. Антиретровирусна терапия - историческо развитие и групи антиретровирусни медикаменти. - Български медицински журнал, 4, 2010, № 29, 7-21.Search in Google Scholar

2. Adikwu, E., N. Brambaifa, Deo Oputiri and Oru-Bo Precious Geoffrey. Antiretroviral toxicity and oxidative stress. - Am. J. Pharmacol. Toxicol. 8 (4): 187-196, 2013.10.3844/ajptsp.2013.187.196Search in Google Scholar

3. Arnaudo, E., M. Dalakas, S. Shanske et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. - Lancet, 1991, 337:508-510.10.1016/0140-6736(91)91294-5Search in Google Scholar

4. Atiba, A. S., D.P. Oparinde, A. K. Jimoh et al. Oxidative stress and serum selenium in HIVpatients on different antiretroviral regimen. - Greener J. Med. Sci., 2012, 2: 163-167.10.15580/GJMS.2012.5.110612232Search in Google Scholar

5. Becher, F., A. Pruvost, D. Schlemmer et al. Significant levels of intracellular stavudine triphosphateare found in HIV-infected zidovudine-treated patients. - AIDS 2003, 17:555-61.10.1097/00002030-200303070-00011Search in Google Scholar

6. Ben-Romano, R., A. Rudich, S. Etzion et al. Nelfi navir induces adipocyte insulin resistance through the induction of oxidative stress: Differential protective effect of antioxidant agents. - Antivir. Ther. 2006, 11: 1051-1060.10.1177/135965350601100812Search in Google Scholar

7. Berhane, K, R. Karim, M. Cohen, L. Masri-Lavine et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women‘s Interagency HIV Study. - J Acquir Immune Defic Syndr. 2004;37(2):1245.10.1097/01.qai.0000134759.01684.27Search in Google Scholar

8. Bonora, S., M. Boffi to, A. D’Avolio et al. Detection of stavudine concentrations in plasma of HIVinfected patients taking zidovudine. - AIDS 2004, 18:577-8.10.1097/00002030-200402200-00031Search in Google Scholar

9. Brinkman, K., J. Smeitink, J. Romijn, P. Reiss. Mitochondrial toxicity induced by nucleoside-analoguereverse- transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapyrelated lipodystrophy. - Lancet 1999, 354:1112-5.10.1016/S0140-6736(99)06102-4Search in Google Scholar

10. Cameron, D., M. Heath-Chiozzi, S. Danner et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. - Lancet 1998, 351:543-9.10.1016/S0140-6736(97)04161-5Search in Google Scholar

11. Carr, A., J. Miller, M. Law, D. Cooper. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. - AIDS 2000, 14:F25-F32.10.1097/00002030-200002180-0000110716495Search in Google Scholar

12. Carr, A., D. Cooper. Adverse effects of antiretroviral therapy. - Lancet 2001; 356:1423-30.10.1016/S0140-6736(00)02854-3Search in Google Scholar

13. Chndra, S., D. Mondal and K.C. Agrawal. HIV-1protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release:Protection with thymoquinone, experim. - Biol. Med. 2009, 234: 442-453.10.3181/0811-RM-317Search in Google Scholar

14. Chun, T. W. et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. - AIDS 24(18): 2803-8. November 27, 2010.Search in Google Scholar

15. Cohen, C., J. Andrade-Villanueva, B. Clotet et al. Rilpivirine versus efavirenz with two background nucleoside or NRTIs in treatment-naïve adults infected with HIV- 1(THRIVE): a phase 3, randomized non-inferiority trial. - Lancet 2011, 378(9787):229-37.10.1016/S0140-6736(11)60983-5Search in Google Scholar

16. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. - Lancet 1994, 343:871-81.10.1016/S0140-6736(94)90006-XSearch in Google Scholar

17. Cossarizza, A. and G. Moyle. Antiretroviral nucleoside and nucleotide analogues and mitochondria. - AIDS 2004, 18: 137-151.10.1097/00002030-200401230-0000215075530Search in Google Scholar

18. Côté, H., B. Yip, J. Asselin et al. Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodefi ciency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. - J Infect Dis 2003, 187:1972-6.10.1086/37535312792876Search in Google Scholar

19. Côté, H., A. Magil, M. Harrig et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. - Antivir Ther 2006, 11:79-86.10.1177/135965350601100108Search in Google Scholar

20. Elias, A. and N. Brambaifa, 2013. Concentration-effect, incidence and mechanism of nevirapine hepatotoxicity. - Am. J. Pharmacol. Toxicol., 8: 20-30.10.3844/ajptsp.2013.20.30Search in Google Scholar

21. Elias, A., O. Deo, O. Geoffrey and D. Enimeya. Nevirapine hepatotoxicity: Implications of risk factors. - Am. J. Pharm. Toxicol. 8: 2013, 51-63.10.3844/ajptsp.2013.51.63Search in Google Scholar

22. Elias, A., N. Brambaifa et al. Antiretroviral toxicity and oxidative stress. - Am. J. Pharmacol. Toxicol. 8 (4): 187-196, 2013.10.3844/ajptsp.2013.187.196Search in Google Scholar

23. Eron, J. HIV-1 protease inhibitors. - Clin Infect Dis 2000, 30 Suppl 2: S160-170.10.1086/313853Search in Google Scholar

24. Fellay, J., K. Boubaker et al. Prevalence of adverse events associated with potent antiretroviral treatment:Swiss HIV Cohort Study, - Lancet 2001; 358(9290); 1323-1327.10.1016/S0140-6736(01)06413-3Search in Google Scholar

25. Galli, M., A. Ridolfo, F. Adorni et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. - JAIDS 2002, 29(1):21-31.10.1097/00042560-200201010-00003Search in Google Scholar

26. Glesby, D. R. Overview of mitochondrial toxicity of nucleoside reverse transcriptase inhibitors. - IAS-USA, 10, 2002, № 1.Search in Google Scholar

27. Hassan, A., A. A. Babadoko, A. I. Mamman and S. Ahmed. Zidovudine induced pure red cell aplasia: A case report. - Niger J. Med., 2009, 18: 332-333.10.4314/njm.v18i3.51210Search in Google Scholar

28. Hill, A., W. Sawyer and B. Gazzard. Effects of fi rst-line use of nucleoside analogues: Efavirenz and ritonavir-boosted protease inhibitors on lipid levels. - HIV Clin. Trials. 2009, 10: 1-12.10.1310/hct1001-1Search in Google Scholar

29. Hoffman, C., J. Rockstroh. HIV 2012/2013. Hamburg. - Medizin Fokus Verlag, 2012.Search in Google Scholar

30. Hughes, P., E. Cretton-Scott, A. Teague and T. M. Wensel. Protease inhibitors for patients with HIV-1 infection: A comparative overview. P T., 2011, 36: 332-345.Search in Google Scholar

31. Izzedine, H., J. Hulot, D. Vittecoq et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. - Nephrol Dial Transplant 2005, 20:743-6.10.1093/ndt/gfh658Search in Google Scholar

32. James, C., P. Lee and M. Sweet. Rilpivirine: A second-generation nonnucleoside reverse transcriptase inhibitor. - Am. J. Health-Syst. Pharm., 2012, 69: 857-861.10.2146/ajhp110395Search in Google Scholar

33. Jena, A., R. Sachdeva, A. Sharma and A. Wanchu. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: A 24-week prospective Study. J. - Int.Assoc. Providers of AIDS Care, 2009, 8: 318-322.10.1177/1545109709343967Search in Google Scholar

34. Lewis, W. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: Experimental clarifications and persistent clinical questions. -Anti. Res. 2003, 58: 189-197.10.1016/S0166-3542(03)00069-XSearch in Google Scholar

35. Mallon, P., P. Unemori, R. Sedwell et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. - J Infect Dis., 191, 2005, № 10, 1686-1696.10.1086/42969715838796Search in Google Scholar

36. Mandas, A., E. Lorio, M. Congiu, C. Balestrieri and A. Mereu et al. Oxidative imbalance in HIV- 1 infected patients treated with antiretroviraltherapy. - J. Biomed. Biotechnol., 2009, 18: 67-79.10.1155/2009/749575276804219884983Search in Google Scholar

37. Manfredi, R., L. Calza. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl. - AIDS, 20, 2006, № 17, 2233-2236.10.1097/QAD.0b013e3280110cae17086066Search in Google Scholar

38. Martinez, E., J. Arnaiz, D. Podzamczer et al. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with HIV infection. - N Eng J Med 2003; 349:1036-1046.10.1056/NEJMoa02158912968087Search in Google Scholar

39. Masia, M., S. Padilla, E. Bernal, M. V. Almenar and J. Molina et al. Infl uence of antiretroviral therapy on oxidative stress and cardiovascular risk:A prospective cross-sectional study in HIV-infected patients. - Clin. Therap., 2007, 29: 448-455.10.1016/j.clinthera.2007.07.02517825696Search in Google Scholar

40. Mbuagbaw, L., J. Irlam, A. Spaulding et al. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial therapy of HIV infection in antiretroviral - naïve individuals. - Cochrane Database Syst Rev 2010,12:CD004246.10.1002/14651858.CD004246.pub321154355Search in Google Scholar

41. Milazzo, L., B. Menzaghi, I. Caramma, M. Nasi and O. Sangaletti et al. Effect of antioxidants on mitochondrial function in HIV-1-related lipoatrophy: A pilot study. - AIDS 2010, 26: 1207-1214.10.1089/aid.2010.002420977356Search in Google Scholar

42. Moyle, G., M. Sadler. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. - Drug Safety 1998, 19:481-94.10.2165/00002018-199819060-000059880091Search in Google Scholar

43. Nolan, D. Metabolic complications associated with HIV protease inhibitor therapy. - Drugs 2003, 63:2555-74.10.2165/00003495-200363230-0000114636077Search in Google Scholar

44. Noor, M. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: Cellular mechanisms and clinical implications. - Curr. HIV/AIDS Rep., 2007, 4: 126-134.10.1007/s11904-007-0019-417883998Search in Google Scholar

45. Nunez, M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. - Hepatology 2010, 52, № 3: 1143-1155.10.1002/hep.2371620812358Search in Google Scholar

46. Ouyang, D., D. Shapiro, M. Lu et al. Increased risk of hepatotoxicity in HIV - infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. - AIDS 2009.23:2425-2430.10.1097/QAD.0b013e32832e34b1278365319617813Search in Google Scholar

47. Peters, P., J. Striner, M. McConnell et al. Nevirapine-associated hepatotoxicity was not predicted by CD 4 count>250 cells/ml, among women in Zambia, Thailand and Kenya. - HIV Med 2010;11:650-60.10.1111/j.1468-1293.2010.00873.x20659176Search in Google Scholar

48. Podzamczer, D., E. Ferrer, E. Consiglio et al. A randomized clinical trial comparing nelfi navir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). - Antivir.Ther. 2002, 7:81-90.10.1177/135965350200700202Search in Google Scholar

49. Redig, A., N. Berliner. Pathogenesis and clinical implications of HIV-related anemia in 2013. - Hematology Am Soc Hematol Educ Program. 2013;2013:377-81.10.1182/asheducation-2013.1.37724319207Search in Google Scholar

50. Regidor, D., R. Detels, E. Breen, D. Widney et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. - AIDS 2011:303-314.10.1097/QAD.0b013e32834273ad332264421192231Search in Google Scholar

51. Rivero, A. and A. Jose. Liver toxicity induced by non-nucleosidereverse transcriptase inhibitors. - J.Antimicrob. Chemother. 2009, 59: 342-346.10.1093/jac/dkl52417255142Search in Google Scholar

52. Sanne, I., H. Mommeja-Marin, J. Hinkle et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. - J Infect Dis 2005;191:825-9.10.1086/42809315717255Search in Google Scholar

53. Storfer, S., J. Leith, P. Piliero, D. Hall. Analysis of hepatic events within the 2NN study: controlling for ethnicity and CD4+ count at initiation of nevirapine therapy. - Abstract PE9.6/2. 10th EACS 2005.Dublin.Search in Google Scholar

54. Tebas, P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: Pathogenesis, prevention and treatment options. - J. Acquir. Immun. Defi c. Syndr. 2008, 49: S86-92.10.1097/QAI.0b013e31818651e618725817Search in Google Scholar

55. Terry, L., E. Sprinz, R. Stein, N. Medeiros and J. Oliveira et al.Exercise training in HIV-1- infected individuals with dyslipidemia and lipodystrophy. - Med. Sci. Sports. Exerc.2006, 38: 411-417.10.1249/01.mss.0000191347.73848.8016540826Search in Google Scholar

56. Torti C, S. Costarelli, A. De Silvestri et al. Analysis of severe hepatic events associated with nevirapine- containing regimens: CD4+ Th cell count and gender in hepatitis C seropositive and seronegative patients. - Drug Saf 2007, 30:1161-9.10.2165/00002018-200730120-0000818035868Search in Google Scholar

57. Vander Valk, M., Reiss P. Lipid profiles associated with antiretroviral drug choices. - Curr Opin Infect Dis2003, 16: 19-23.10.1097/00001432-200302000-0000412821825Search in Google Scholar

58. Walker, U., B. Setzer, N. Venhoff. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse transcriptase inhibitors. - AIDS 2002, 16(16):2165-73. 10.1097/00002030-200211080-0000912409738Search in Google Scholar